RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Genetic Technologies Stock

Genetic Technologies Debt 2025

Genetic Technologies Debt

-0.15 AUD

Ticker

GTG.AX

ISIN

AU000000GTG7

WKN

893882

In 2025, Genetic Technologies's total debt was -0.15 AUD, a -98.01% change from the -7.32 AUD total debt recorded in the previous year.

Genetic Technologies Aktienanalyse

What does Genetic Technologies do?

Genetic Technologies Ltd is an Australian biotechnology company that was founded in 1989. The company is an internationally recognized provider of genomic analysis procedures and technologies and has been operating in various business sectors since its establishment. Genetic Technologies is headquartered in Melbourne, Australia, and maintains offices in the USA, Europe, and Asia. The company's business model is based on the development and commercialization of genetic analysis systems and technologies. Genetic Technologies serves a wide range of customers, including research institutes, universities, diagnostic laboratories, biotechnology companies, and pharmaceutical companies. The company specializes in the analysis of DNA sequences and offers various genetic testing procedures to, for example, identify genetic risk factors for certain diseases or determine the ancestry of individuals. Genetic Technologies' different business sectors include clinical diagnostics, agriculture, forensic science, and scientific research. The company develops and markets various genetic testing procedures, such as the BREVAGenplus test, which aims to help women determine their risk for breast and ovarian cancer. Genetic Technologies also plays a leading role in agriculture, offering, for example, the CalfStart test, which allows breeders to determine the genetic potential of their calves. In forensic science, Genetic Technologies develops DNA tests that help solve criminal cases and identify perpetrators. Furthermore, the company also provides genetic counseling services. Another important area of Genetic Technologies is the development and commercialization of genetic analysis procedures and technologies. The company holds several patents worldwide for DNA analysis procedures, including the patented non-coding procedure, which represented a significant breakthrough in genomic research. Genetic Technologies' chairman, Dr. Mervyn Jacobson, is a recognized expert in the field of genomic research and has already authored numerous scientific publications on this topic. In addition to its various business sectors and products, Genetic Technologies has also established close relationships with other companies and institutions in the biotechnology industry. For example, the company collaborates closely with the USA-based HudsonAlpha Institute for Biotechnology to jointly develop innovative DNA technologies and procedures. Overall, Genetic Technologies has made a name for itself as a company specializing in the analysis of DNA sequences. Through its innovative products and services, the company has contributed to advancing genomic research and gaining new insights into the genetic basis of diseases and other phenomena. With its broad range of business sectors and international presence, Genetic Technologies is an important player in the biotechnology industry and is likely to further expand in the coming years. Genetic Technologies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Genetic Technologies's Debt Structure

Genetic Technologies's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Genetic Technologies's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Genetic Technologies’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Genetic Technologies’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Genetic Technologies stock

What is the debt of Genetic Technologies this year?

Genetic Technologies has a debt level of -0.15 AUD this year.

What was the debt of Genetic Technologies compared to the previous year?

The debt of Genetic Technologies has increased by -98.01% compared to the previous year dropped.

What are the consequences of high debt for investors in Genetic Technologies?

High debt can pose a risk for investors of Genetic Technologies, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Genetic Technologies?

Low debt means that Genetic Technologies has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Genetic Technologies affect the company?

An increase in debt of Genetic Technologies can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Genetic Technologies affect the company?

A reduction in debt of Genetic Technologies can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Genetic Technologies?

Some factors that can influence the debt of Genetic Technologies include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Genetic Technologies so important for investors?

The debts of Genetic Technologies are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Genetic Technologies take to change the debt?

To change the debt, Genetic Technologies can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Genetic Technologies pay?

Over the past 12 months, Genetic Technologies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Genetic Technologies is expected to pay a dividend of 0 AUD.

What is the dividend yield of Genetic Technologies?

The current dividend yield of Genetic Technologies is .

When does Genetic Technologies pay dividends?

Genetic Technologies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Genetic Technologies?

Genetic Technologies paid dividends every year for the past 0 years.

What is the dividend of Genetic Technologies?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Genetic Technologies located?

Genetic Technologies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Genetic Technologies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Genetic Technologies from 9/2/2025 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 9/2/2025.

When did Genetic Technologies pay the last dividend?

The last dividend was paid out on 9/2/2025.

What was the dividend of Genetic Technologies in the year 2024?

In the year 2024, Genetic Technologies distributed 0 AUD as dividends.

In which currency does Genetic Technologies pay out the dividend?

The dividends of Genetic Technologies are distributed in AUD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Genetic Technologies

Our stock analysis for Genetic Technologies Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Genetic Technologies Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.